A study showed that the protein expression of RIPK1, RIPK3, and MLKL was higher in postmortem substantia nigra samples from patients with PD than in control individuals, which is consistent with the pathological features observed in MS and ALS [111]. This evidence concerns the gene RIPK3 and myeloid sarcoma.